Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OPK
HoldHot AirOPKO Health, Inc. · Healthcare · United States · $1.1B · Avg Vol: $4M/d
COMPANY DESCRIPTION
OPKO Health, Inc. is a diversified healthcare company operating through two main segments: diagnostics, including clinical laboratory services and molecular diagnostics, and pharmaceuticals, focused on specialty drugs and clinical development. The company seeks to leverage proprietary technologies like 4Kscore and RAYALDEE within its integrated model to address significant medical needs. OPKO aims to combine diagnostic insights with therapeutic innovation to provide comprehensive patient solutions globally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0B | 863.5M | 713.1M | 606.9M | -15.5% | 587.9M | 569.9M | 588.9M | -1.5% |
| EPS | -0.46 | -0.25 | -0.08 | -0.30 | — | -0.07 | -0.22 | -0.28 | — |
| Shares | 772.7M | 773.3M | 671.6M | 759.1M | -1.8% | 746.3M | — | — | — |
| Debt | 305.5M | 326.6M | 504.4M | 396.8M | 9.1% | 398.1M | — | — | — |
| Equity | 1.6B | 1.4B | 1.4B | 1.3B | -6.7% | — | — | — | — |
| Op CF | -95.2M | -28.2M | -183.5M | -178.5M | — | -123.4M | — | — | — |
| Inv CF | 91.0M | -18.2M | 352.2M | 230.3M | — | — | — | — | — |
| Fin CF | 23.0M | -11.3M | 184.2M | -118.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OPK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OPK | OPKO Health, Inc.(you) | $1.1B | 38 | Hold |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
| FLGT | Fulgent Genetics, Inc. | $540M | 45 | Hold |
| PSNL | Personalis, Inc. | $1.8B | 24 | Sell |
| NEO | NeoGenomics, Inc. | $2.3B | 47 | Hold |
| ADPT | Adaptive Biotechnologies Corporation | $4.0B | 38 | Hold |
| FRNM | Freenome, Inc. | $1.6B | 18 | Strong Sell |
| WGS | GeneDx Holdings Corp. | $2.6B | 24 | Sell |
| GRAL | GRAIL, Inc. | $3.6B | 28 | Sell |
| BDSX | Biodesix, Inc. | $283M | 29 | Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%